logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Merck & Invivyd in Today's December 18, 2023 News

Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important new approval for Merck's ( MRK ) Keytruda product, and exciting promising trial results for the firm Invivyd, Inc. ( IVVD ) viral protection....

Read More

December 18, 2023

0

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy for Type 1Diabetes

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy CRISPR Therapeutics ( CRSP ) and ViaCyte, Inc. , announced that Health Canada approved their Clinical Trial Application ( CTA ) for the product VCTX210, an...

Read More

November 16, 2021

0

GlaxoSmithKline and Vir Biotechnology Announced U.S. Gov't Contracts to Purchase $1B of Sotrovimab for COVID-19

GlaxoSmithKline and Vir Biotechnology Announces US Gov't Contracts to Purchase Sotrovimab for COVID-19 GlaxoSmithKline plc ( GSK ) and Vir Biotechnology ( VIR ) announced US government contracts totaling around $1 billion (USD) to purchase sotrovimab - an investigational monoclonal...

Read More

November 17, 2021

0

Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease

Novo Nordisk in the NEWS Novo Nordisk ( NVO ) and Cardior Pharmaceuticals announced that Novo Nordisk agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones...

Read More

March 25, 2024

0

Ionis Pharmaceuticals Announces that Pfizer Reported Positive Results of Vupanorsen for Cardiovascular Risk Reduction and Severe Hypertriglyceridemia

Ionis Pharmaceuticals Announced Pfizer Update of Vupanorsen Ionis Pharmaceuticals ( IONS ) announced that Pfizer's ( PFE ) update of the Phase 2b study of vupanorsen met its primary endpoin, achieving a statistically significant reduction in non-HDL-C at all doses tested...

Read More

November 25, 2021

0

The Omicron Variant and the Bizarre Stock Market Chaos

The Bizarre Assessment of Biotech Firms in the Stock Market The Clinical-Stage Biotechnology Firms  We are witnessing inexplicable evaluations of clinical-stage biotechnology companies. Bizarre is the best description of this group’s assessment which is based on incomes that do not...

Read More

November 30, 2021

0

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

CymaBay Therapeutics in the NEWS CymaBay Therapeutics ( CBAY ) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 ( IL-31 ) levels and its correlation with pruritus improvement in people with primary biliary cholangitis...

Read More

January 3, 2024

0

BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now

BioStem Technologies to Release Fourth Quarter Results BioStem Technologies ( BSEM ) is hosting a conference call and webcast today, April 1, 2024 at 4:30 PM ET. The call will include a discussion of fourth quarter 2023 financial results in...

Read More

April 1, 2024

0

Great News: Vertex Pharmaceuticals Announced Successful Phase 2 Study Results of VX-147

Vertex Pharmaceuticals Phase 2 Results of VX-147 Vertex Pharmaceuticals ( VRTX ) announced today that, in a Phase 2 proof-of-concept ( POC ) study in patients with APOL1-mediated focal segmental glomerulosclerosis ( FSGS ), VX-147, on top of standard of...

Read More

December 1, 2021

0

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson in the NEWS Today, Apr. 5, 2024 - Johnson & Johnson ( JNJ ) and Shockwave Medical ( SWAV ) announced that they entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding...

Read More

April 5, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 152
  • 153
  • 154
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy